6 days ago
Millions of Americans recently received unwelcome news about their cell phone bills.
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#august #plans
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#august #plans
7 days ago
RF Industries, Ltd. (NASDAQ:RFIL) reported stronger fiscal third-quarter results on September 14. Revenue increased 21% to $23.96 million for the quarter ended July 31, 2026, while operating income reached approximately $1.8 million, compared with $720,000 a year earlier.
The next question is whether new orders can sustain that performance. Quarterly bookings totaled $22.5 million, below revenue. Backlog stood at $18.6 million at quarter-end and increased to $19.8 million by September 14.
Bookings measure new orders, including modifications or cancellations of earlier orders. Backlog represents orders received for which revenue has yet to be recognized.
RF Industries, Ltd. (NASDAQ:RFIL) improved both sales and profitability. Gross margin increased to 35.6% from 34% a year earlier, helping operating income grow much faster than revenue.
Management attributes the margin expansion to a shift toward customized cabling and integrated systems. These offerings involve more engineering and larger projects than traditional component sales. Competing on technical capability and customer requirements could support stronger relationships and repeat business.
#earlier
The next question is whether new orders can sustain that performance. Quarterly bookings totaled $22.5 million, below revenue. Backlog stood at $18.6 million at quarter-end and increased to $19.8 million by September 14.
Bookings measure new orders, including modifications or cancellations of earlier orders. Backlog represents orders received for which revenue has yet to be recognized.
RF Industries, Ltd. (NASDAQ:RFIL) improved both sales and profitability. Gross margin increased to 35.6% from 34% a year earlier, helping operating income grow much faster than revenue.
Management attributes the margin expansion to a shift toward customized cabling and integrated systems. These offerings involve more engineering and larger projects than traditional component sales. Competing on technical capability and customer requirements could support stronger relationships and repeat business.
#earlier
7 days ago
Bloom Energy Corporation (NYSE:BE) garnered significant investor attention after it unveiled a new 800V DC-native fuel-cell power architecture on September 16, designed to supply continuous direct current to the next generation of AI data centers.
These solid-oxide fuel cells can generate continuous 800V DC power natively, rather than producing AC power that then has to be converted into DC that AI computing equipment ultimately consumes. This potentially removes several conversion stages, such as transformers and switchgear, thus lowering capital cost and energy losses.
Bloom claims that its technology can cut non-compute capital expenditures for a 1 GW data center by $3.6 billion, or 27%, and lower five-year total cost of ownership by $5.5 billion, or 9%, compared to traditional AC-based infrastructure.
With this technology, Bloom Energy is targeting one of the biggest bottlenecks in the ongoing AI boom – securing large amounts of reliable power quickly and economically. If 800V DC becomes widely adopted across AI data centers, the company will benefit not only from the soaring power demand, but also from a broader shift in how that power is generated and delivered.
Bloom Energy pointed to Nvidia's planned adoption of 800V DC architecture beginning with Rubin Ultra and Kyber systems as an indication of where data center power infrastructure is heading. In its 2026 Mid-Year Data Center Power Report, Bloom claimed that data center leaders expect DC-based architectures to account for 58% of new deployments by 2030, potentially creating a significant market for technologies designed around direct-current power delivery.
#energy #architecture
These solid-oxide fuel cells can generate continuous 800V DC power natively, rather than producing AC power that then has to be converted into DC that AI computing equipment ultimately consumes. This potentially removes several conversion stages, such as transformers and switchgear, thus lowering capital cost and energy losses.
Bloom claims that its technology can cut non-compute capital expenditures for a 1 GW data center by $3.6 billion, or 27%, and lower five-year total cost of ownership by $5.5 billion, or 9%, compared to traditional AC-based infrastructure.
With this technology, Bloom Energy is targeting one of the biggest bottlenecks in the ongoing AI boom – securing large amounts of reliable power quickly and economically. If 800V DC becomes widely adopted across AI data centers, the company will benefit not only from the soaring power demand, but also from a broader shift in how that power is generated and delivered.
Bloom Energy pointed to Nvidia's planned adoption of 800V DC architecture beginning with Rubin Ultra and Kyber systems as an indication of where data center power infrastructure is heading. In its 2026 Mid-Year Data Center Power Report, Bloom claimed that data center leaders expect DC-based architectures to account for 58% of new deployments by 2030, potentially creating a significant market for technologies designed around direct-current power delivery.
#energy #architecture
7 days ago
Millions of Americans recently received unwelcome news about their cell phone bills.
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#Consumer
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ******* ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#Consumer
7 days ago
It's been a disappointing couple of years for shareholders of biotechnology outfit CRISPR Therapeutics (NASDAQ: CRSP). This stock's barely up since the end of 2022, lagging the broad market's gains. It's not the performance that investors keeping tabs on this company were expecting, given its potential.
Don't be discouraged, though. While still speculative like most young biotech names, CRISPR Therapeutics remains a compelling prospect for investors who can stomach the risk and its inevitable volatility. Here's why.
Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our **** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
On the off-chance you're reading this and aren't already familiar with the company, CRISPR Therapeutics is a drug developer that specializes in gene editing.
It's probably an area you've heard a great deal about. No gene-editing drugs were actually on the market in the United States until CRISPR Therapeutics' Casgevy was approved by the FDA as a treatment for sickle cell disease in late 2023. Any and all gene therapies currently on the market followed this pioneer's foray. Being first is a well-deserved accolade for the company, too, which was co-founded by Dr. Emmanuelle Charpentier, who was one of the co-discoverers of the CRISPR/Cas9 gene-editing mechanism that makes Casgevy work.
#crispr #gene #company
Don't be discouraged, though. While still speculative like most young biotech names, CRISPR Therapeutics remains a compelling prospect for investors who can stomach the risk and its inevitable volatility. Here's why.
Missed AI's "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our **** ysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
On the off-chance you're reading this and aren't already familiar with the company, CRISPR Therapeutics is a drug developer that specializes in gene editing.
It's probably an area you've heard a great deal about. No gene-editing drugs were actually on the market in the United States until CRISPR Therapeutics' Casgevy was approved by the FDA as a treatment for sickle cell disease in late 2023. Any and all gene therapies currently on the market followed this pioneer's foray. Being first is a well-deserved accolade for the company, too, which was co-founded by Dr. Emmanuelle Charpentier, who was one of the co-discoverers of the CRISPR/Cas9 gene-editing mechanism that makes Casgevy work.
#crispr #gene #company
7 days ago
Some offers on this page are from advertisers who pay us, which may affect which products we write about, but not our recommendations. See our Advertiser Disclosure.
The U.S. Bank Shield™ Visa® Visa Card is a 0% APR card with a lengthy intro period lasting 21 billing cycles for both balance transfers and new purchases. It's a great option for debt payoff, but you may also want to consider its long-term value before you apply.
$20 annual statement credit: Earn up to $20 as an annual statement credit when you make purchases with your card over 11 consecutive calendar months.
Cell phone protection: Worth up to $600 per claim (with a $100 deductible) in case of theft or damage to your phone. You can make one claim every 12 months and must pay your monthly cell phone bill with your card to qualify.
#credit
The U.S. Bank Shield™ Visa® Visa Card is a 0% APR card with a lengthy intro period lasting 21 billing cycles for both balance transfers and new purchases. It's a great option for debt payoff, but you may also want to consider its long-term value before you apply.
$20 annual statement credit: Earn up to $20 as an annual statement credit when you make purchases with your card over 11 consecutive calendar months.
Cell phone protection: Worth up to $600 per claim (with a $100 deductible) in case of theft or damage to your phone. You can make one claim every 12 months and must pay your monthly cell phone bill with your card to qualify.
#credit
8 days ago
A column of black smoke has been seen near Riyadh's international airport hours after air raid alerts were issued in the Saudi capital.
It was the first time residents had been given an alert and urged to stay indoors since a recent escalation in the conflict with Iran-backed Houthi militants in neighbouring Yemen.
A number of apparent explosions have since been heard in the capital and major problems reported at King Khalid International Airport, with the tracking website FlightRadar24 reporting long delays and cancellations.
One report suggested a fuel tank had been set on fire near the airport. There has been no official comment from Saudi authorities.
An AFP journalist reported that firefighters could be seen trying to extinguish the flames of a burnt-out fuel tank belonging to state oil and gas company Aramco.
#since
It was the first time residents had been given an alert and urged to stay indoors since a recent escalation in the conflict with Iran-backed Houthi militants in neighbouring Yemen.
A number of apparent explosions have since been heard in the capital and major problems reported at King Khalid International Airport, with the tracking website FlightRadar24 reporting long delays and cancellations.
One report suggested a fuel tank had been set on fire near the airport. There has been no official comment from Saudi authorities.
An AFP journalist reported that firefighters could be seen trying to extinguish the flames of a burnt-out fuel tank belonging to state oil and gas company Aramco.
#since
8 days ago
Millions of Americans recently received unwelcome news about their cell phone bills.
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ***** ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#month #americans #august #older
In late June, T-Mobile (TMUS) said it was retiring over 1,000 older plans, shifting customers to newer offerings at an added cost of as much as $6 per line per month. And starting in August, AT&T (T) hiked rates on some of its older plans by $10 to $20 and increased a monthly per-line fee by $1.
The changes contributed to a steep 5.9% jump in Americans' wireless bills from July to August alone, according to Consumer Price Index data. It was the largest single-month jump since the Bureau of Labor Statistics began tracking the category nearly three decades ago.
In a twist, last month's rising phone bills may have helped convince the Federal Reserve to implement its first interest rate hike in three years. The steep price jump likely contributed about 10 basis points of August's 0.3% month-over-month rise in core consumer prices, according to Wall Street ***** ysts. The hotter-than-expected jump in this category, which strips out price changes in the particularly volatile food and energy sectors, helped cement expectations for the Fed's 25 basis point hike to benchmark rates last Wednesday.
Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments
#month #americans #august #older
8 days ago
On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
8 days ago
On August 6, Millicom International Cellular (NASDAQ:TIGO) released its second-quarter 2026 results, and the numbers pulled in two directions at once. Revenue jumped 59.4% year over year to $2.18 billion, while Adjusted EBITDA crossed $1 billion for the first time in the company's history at $1.01 billion, up 58% from a year earlier. Yet net profit attributable to company owners fell 83.9% to just $109 million. Investors weighing this quarter have to decide which of those two stories actually describes the business.
The headline figures are hard to ignore. Service revenue reached $2.04 billion in the quarter, up 60.1% year over year, while H1 2026 revenue climbed to $4.16 billion from $2.74 billion a year earlier, a 52.3% increase. Equity free cash flow hit a quarterly record of $327 million, up 50.1% from a year ago, and leverage actually fell to 2.73x even after Millicom absorbed acquisitions in Colombia, Ecuador and Uruguay. That combination, rising cash generation alongside falling leverage during an acquisition spree, is the kind of signal that tends to matter more than a single quarter's headline growth rate.
Management is backing that signal with cash. Millicom already declared a $3.00 per share dividend in May, to be paid out quarterly over the next 12 months, and on August 5, the board approved an additional interim dividend of $1.50 per share, split into two $0.75 installments due January 15, 2027, and April 15, 2027. The company also raised its full-year 2026 equity free cash flow guidance from at least $900 million to around $1.1 billion, while lowering its year-end leverage target from about 2.5x to below 2.5x. CEO Marcelo Benitez pointed to Ecuador and Uruguay as evidence the integration playbook works, saying both markets have reached margins and cash generation broadly in line with the Millicom average, with Colombia and Chile now showing early improvement on the same path.
Strip out the acquisitions, and the picture looks far less dramatic. Organic revenue growth was just 4.3% in the quarter and 4.2% for the first half, a fraction of the 59.4% and 52.3% reported figures. Most of what shows up in the headline number is Millicom buying its way to a bigger top line, not the existing business accelerating on its own.
The profit line raises a separate question. Net profit attributable to company owners dropped to $109 million from $676 million a year earlier, and the first-half figure fell 74.9% to $218 million from $869 million, even as EBITDA and cash flow set records over the same stretch. That gap between a surging EBITDA number and a collapsing bottom line is the kind of divergence that deserves scrutiny rather than a shrug. Capital spending is climbing too, up 51.2% to $234 million in the quarter and 48.8% to $426 million for the half, running well ahead of the organic growth rate it is meant to fund. And the balance sheet is still in motion: in July 2026, Bolivia took on five new local bank loans totaling roughly $44 millio
The headline figures are hard to ignore. Service revenue reached $2.04 billion in the quarter, up 60.1% year over year, while H1 2026 revenue climbed to $4.16 billion from $2.74 billion a year earlier, a 52.3% increase. Equity free cash flow hit a quarterly record of $327 million, up 50.1% from a year ago, and leverage actually fell to 2.73x even after Millicom absorbed acquisitions in Colombia, Ecuador and Uruguay. That combination, rising cash generation alongside falling leverage during an acquisition spree, is the kind of signal that tends to matter more than a single quarter's headline growth rate.
Management is backing that signal with cash. Millicom already declared a $3.00 per share dividend in May, to be paid out quarterly over the next 12 months, and on August 5, the board approved an additional interim dividend of $1.50 per share, split into two $0.75 installments due January 15, 2027, and April 15, 2027. The company also raised its full-year 2026 equity free cash flow guidance from at least $900 million to around $1.1 billion, while lowering its year-end leverage target from about 2.5x to below 2.5x. CEO Marcelo Benitez pointed to Ecuador and Uruguay as evidence the integration playbook works, saying both markets have reached margins and cash generation broadly in line with the Millicom average, with Colombia and Chile now showing early improvement on the same path.
Strip out the acquisitions, and the picture looks far less dramatic. Organic revenue growth was just 4.3% in the quarter and 4.2% for the first half, a fraction of the 59.4% and 52.3% reported figures. Most of what shows up in the headline number is Millicom buying its way to a bigger top line, not the existing business accelerating on its own.
The profit line raises a separate question. Net profit attributable to company owners dropped to $109 million from $676 million a year earlier, and the first-half figure fell 74.9% to $218 million from $869 million, even as EBITDA and cash flow set records over the same stretch. That gap between a surging EBITDA number and a collapsing bottom line is the kind of divergence that deserves scrutiny rather than a shrug. Capital spending is climbing too, up 51.2% to $234 million in the quarter and 48.8% to $426 million for the half, running well ahead of the organic growth rate it is meant to fund. And the balance sheet is still in motion: in July 2026, Bolivia took on five new local bank loans totaling roughly $44 millio
8 days ago
On September 8, 2026, CNBC reported that Novartis AG (NYSE:NVS) shares fell about 10% after the company said its experimental drug del-desiran failed to meet its primary goal in a late-stage trial for myotonic dystrophy type 1.
It marked the company's third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen and a separate pause of eight trials of cell therapy rap-cel after three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history.
Remibrutinib provides a major remaining pipeline catalyst since Novartis AG (NYSE:NVS) reported successful late-stage results for remibrutinib in multiple sclerosis. It gives investors a credible growth driver after the failures of pelacarsen and del-desiran. The business expects more remibrutinib data later this year, making the drug an important test of whether its remaining pipeline can help long-term growth.
Novartis still expects 5% to 6% annual sales growth through 2030. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030. That guidance shows the company still expects its overall portfolio and remaining pipeline ******* ets to offset pressure from aging drugs.
The company retains a diversified commercial portfolio. The del-desiran failure removes a potentially important future revenue contributor, but Novartis still makes substantial revenue from its existing medicines. It also retains other pipeline ******* ets. That diversification gives the firm financial capacity to absorb individual clinical failures while it rebuilds investor confidence in its growth pipeline.
#company #remibrutinib
It marked the company's third clinical setback in a week following the earlier failure of cardiovascular drug pelacarsen and a separate pause of eight trials of cell therapy rap-cel after three patient deaths. The decline erased roughly 24 billion Swiss francs, or about $29.6 billion, in market value and put Novartis on pace for one of its worst trading days in company history.
Remibrutinib provides a major remaining pipeline catalyst since Novartis AG (NYSE:NVS) reported successful late-stage results for remibrutinib in multiple sclerosis. It gives investors a credible growth driver after the failures of pelacarsen and del-desiran. The business expects more remibrutinib data later this year, making the drug an important test of whether its remaining pipeline can help long-term growth.
Novartis still expects 5% to 6% annual sales growth through 2030. Management reaffirmed its full-year financial guidance and maintained its target for 5% to 6% compound annual sales growth from 2025 through 2030. That guidance shows the company still expects its overall portfolio and remaining pipeline ******* ets to offset pressure from aging drugs.
The company retains a diversified commercial portfolio. The del-desiran failure removes a potentially important future revenue contributor, but Novartis still makes substantial revenue from its existing medicines. It also retains other pipeline ******* ets. That diversification gives the firm financial capacity to absorb individual clinical failures while it rebuilds investor confidence in its growth pipeline.
#company #remibrutinib
9 days ago
Soybeans closed the midweek session pushing higher into the close, as contracts were 1 ¾ to 3 ½ cents higher. The cmdtyView national average Cash Bean price was up 1 3/4 cents at $12.62 ¾. Soymeal futures were back 20 cents lower to $2.10 across the board, with Soy Oil 50 to 69 points lower.
USDA will update Export Sales data on Thursday morning, as ***** ysts surveyed by Reuters are looking for between 0.9-2.4 MMT in 2026/27 soybean sales in the week ending last Thursday. Soybean meal bookings are seen between 150,000 and 650,000 MT in total, as bean oil is expected in a range of net cancellations of 10,000 and combined sales of 10,000 MT.
Coffee Prices Pressured by Improved Global Supply Outlook
Cocoa Prices Consolidate Below 11.5-Month Highs
Signs of Improving Global Supplies Weigh on Coffee Prices
#thursday #coffee #bean
USDA will update Export Sales data on Thursday morning, as ***** ysts surveyed by Reuters are looking for between 0.9-2.4 MMT in 2026/27 soybean sales in the week ending last Thursday. Soybean meal bookings are seen between 150,000 and 650,000 MT in total, as bean oil is expected in a range of net cancellations of 10,000 and combined sales of 10,000 MT.
Coffee Prices Pressured by Improved Global Supply Outlook
Cocoa Prices Consolidate Below 11.5-Month Highs
Signs of Improving Global Supplies Weigh on Coffee Prices
#thursday #coffee #bean
9 days ago
While the average personal loan interest rate is 12.44%, borrowers with excellent credit may have access to rates as low as 5.96%.
Credit unions tend to offer the lowest overall borrowing costs, with a national average of 10.64% and a legal rate cap of 18% at federal institutions.
Online fintech lenders advertise competitive rates starting just below 6%, though maximum rates can climb up to 36% or higher.
Commercial banks remain competitive, with an average rate of 12%, but they demand a high credit score and solid work history for approval.
Tracking average personal loan rates can help you benchmark your borrowing costs for major goals like consolidating credit cards, financing home renovations or covering emergencies. Because personal loans offer fixed monthly payments, they are a solid tool for eliminating credit card debt, provided your credit profile qualifies you for the lowest market pricing.
#average #rates #lowest #borrowing
Credit unions tend to offer the lowest overall borrowing costs, with a national average of 10.64% and a legal rate cap of 18% at federal institutions.
Online fintech lenders advertise competitive rates starting just below 6%, though maximum rates can climb up to 36% or higher.
Commercial banks remain competitive, with an average rate of 12%, but they demand a high credit score and solid work history for approval.
Tracking average personal loan rates can help you benchmark your borrowing costs for major goals like consolidating credit cards, financing home renovations or covering emergencies. Because personal loans offer fixed monthly payments, they are a solid tool for eliminating credit card debt, provided your credit profile qualifies you for the lowest market pricing.
#average #rates #lowest #borrowing
9 days ago
Soybeans are trading with contracts 3 to 4 cents lower across the front months at midday. The cmdtyView national average Cash Bean price is down 3 3/4 cents at $12.56 ¾. Soymeal futures are back down $1.50 to $2, with Soy Oil 80 to 95 points lower.
USDA will update Export Sales data on Thursday morning, as ***** ysts surveyed by Reuters are looking for between 0.9-2.4 MMT in 2026/27 soybean sales in the week ending last Thursday. Soybean meal bookings are seen between 150,000 and 650,000 MT in total, as bean oil is expected in a range of net cancellations of 10,000 and combined sales of 10,000 MT.
Coffee Prices Retreat on Ideal Growing Weather in Brazil and Vietnam
Cocoa Prices Fall on Signs of Adequate Supplies
Signs of Adequate Supplies Weigh on Cocoa Prices
#cocoa #supplies #soybean
USDA will update Export Sales data on Thursday morning, as ***** ysts surveyed by Reuters are looking for between 0.9-2.4 MMT in 2026/27 soybean sales in the week ending last Thursday. Soybean meal bookings are seen between 150,000 and 650,000 MT in total, as bean oil is expected in a range of net cancellations of 10,000 and combined sales of 10,000 MT.
Coffee Prices Retreat on Ideal Growing Weather in Brazil and Vietnam
Cocoa Prices Fall on Signs of Adequate Supplies
Signs of Adequate Supplies Weigh on Cocoa Prices
#cocoa #supplies #soybean
9 days ago
Andy Burnham has warned of a "challenging" Budget as the Iran war drives up oil and gas prices.
The Prime Minister said he would do what he could to ease the cost of living after the Middle East conflict pushed price rises to a five-month high.
Mr Burnham branded the latest up-tick in inflation a "concern", as official figures showed the headline rate rose from 2.9pc in July to 3.1pc in August. However, he insisted that Britain's economy had shown "resilience across the board".
His warning of a difficult Budget in October will raise fears of tax rises as the fallout from the Iran war continues to weaken the public finances and erode the Government's fiscal headroom.
Oxford Economics has warned that the Chancellor will need to find £11bn if he wants to maintain the same wiggle room on the Treasury's books.
#warned #rises
The Prime Minister said he would do what he could to ease the cost of living after the Middle East conflict pushed price rises to a five-month high.
Mr Burnham branded the latest up-tick in inflation a "concern", as official figures showed the headline rate rose from 2.9pc in July to 3.1pc in August. However, he insisted that Britain's economy had shown "resilience across the board".
His warning of a difficult Budget in October will raise fears of tax rises as the fallout from the Iran war continues to weaken the public finances and erode the Government's fiscal headroom.
Oxford Economics has warned that the Chancellor will need to find £11bn if he wants to maintain the same wiggle room on the Treasury's books.
#warned #rises
9 days ago
By Katharine Jackson and Mike Scarcella
WASHINGTON, Sept 17 (Reuters) - A federal judge ordered President Donald Trump's administration on Thursday to provide at least 30 days' notice before taking any steps to demolish the Kennedy Center, the landmark performing arts venue that has become a flashpoint in his efforts to reshape the U.S. capital.
U.S. District Judge Christopher Cooper issued the order after lawyers for a Democratic congresswoman who is suing to keep the venue open and Trump's name off its facade submitted new evidence citing the Republican president's comments on Wednesday referring to demolishing the Kennedy Center.
"I think that the Trump administration should certainly have recognition. Because frankly, if we don't do that, it's going to close. It'll end up being ripped down," Trump told reporters in North Carolina, referring to putting his name on the facility established by Congress and opened in 1971 as a memorial to slain President John Kennedy.
Matt Floca, the Kennedy Center's Trump-backed executive director, said in a court filing earlier on Thursday that the building was being temporarily closed to ****** s safety risks in areas "exhibiting severe structural deterioration."
#president #venue
WASHINGTON, Sept 17 (Reuters) - A federal judge ordered President Donald Trump's administration on Thursday to provide at least 30 days' notice before taking any steps to demolish the Kennedy Center, the landmark performing arts venue that has become a flashpoint in his efforts to reshape the U.S. capital.
U.S. District Judge Christopher Cooper issued the order after lawyers for a Democratic congresswoman who is suing to keep the venue open and Trump's name off its facade submitted new evidence citing the Republican president's comments on Wednesday referring to demolishing the Kennedy Center.
"I think that the Trump administration should certainly have recognition. Because frankly, if we don't do that, it's going to close. It'll end up being ripped down," Trump told reporters in North Carolina, referring to putting his name on the facility established by Congress and opened in 1971 as a memorial to slain President John Kennedy.
Matt Floca, the Kennedy Center's Trump-backed executive director, said in a court filing earlier on Thursday that the building was being temporarily closed to ****** s safety risks in areas "exhibiting severe structural deterioration."
#president #venue
9 days ago
AI data centers are facing growing power constraints, and the issue is becoming increasingly urgent. New utility capacity can take years to develop and bring online, but hyperscalers cannot afford to wait that long to support their growing computing needs. That gap between supply and demand creates an opportunity for Bloom Energy (BE), which is focused on delivering power where and when hyperscalers like Microsoft (MSFT), Amazon (AMZN), and Alphabet (GOOG) (GOOGL) require it. The fundamentals are now starting to provide support for the growing optimism around its opportunity.
Bloom Energy's technology stands out because it can address the AI power challenge on a much shorter timeline. The company's solid-oxide fuel cells are manufactured in factories and can be moved where required. They can also be deployed much faster than traditional power infrastructure. Instead of waiting years for grid upgrades or additional turbine capacity, data center developers can install Bloom Energy's systems and bring power online in a much shorter timeframe. As AI infrastructure expands, that speed has helped the company establish itself as an increasingly important on-site power vendor. All major U.S. hyperscalers are also providing validation of its position.
Why UBS Just Turned Bearish on NuScale Power Stock
Crude Oil Prices Retreat as Supply Fears Ease
Crude Prices Soar as Global Oil Supplies Continue to Tighten
#bloom #crude
Bloom Energy's technology stands out because it can address the AI power challenge on a much shorter timeline. The company's solid-oxide fuel cells are manufactured in factories and can be moved where required. They can also be deployed much faster than traditional power infrastructure. Instead of waiting years for grid upgrades or additional turbine capacity, data center developers can install Bloom Energy's systems and bring power online in a much shorter timeframe. As AI infrastructure expands, that speed has helped the company establish itself as an increasingly important on-site power vendor. All major U.S. hyperscalers are also providing validation of its position.
Why UBS Just Turned Bearish on NuScale Power Stock
Crude Oil Prices Retreat as Supply Fears Ease
Crude Prices Soar as Global Oil Supplies Continue to Tighten
#bloom #crude
10 days ago
Wasatch Global Investors, an ****** et management company, released its "Long/Short Alpha Fund" Q2 2026 investor letter. The letter can be downloaded here. Small- and mid-cap growth stocks posted significant gains in Q2, led primarily by AI-related companies. The Russell 2500 Index rose 20.26%, while the Wasatch Long/Short Alpha Fund—Investor Class increased by 8.29%. However, the fund faced challenges due to the outperformance of lower-quality companies, which negatively impacted its long positions. Despite trailing the benchmark and some losses in short positions, the fund remains confident in its long portfolio's fundamentals, which have not deteriorated. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Wasatch Long/Short Alpha Fund highlighted Bloom Energy Corporation (NYSE:BE). Bloom Energy Corporation (NYSE:BE), designs and manufactures solid-oxide fuel cell systems for clean, reliable, on-site power generation. On September 15, 2026, Bloom Energy Corporation closed at $259.35 per share. Over the past month, Bloom Energy Corporation returned 25.51%, and its shares are up 225.53% over the past year. Bloom Energy Corporation has a market capitalization of $76.39 billion, and its stock has traded within a 52-week range of $61.37 to $351.28.
Wasatch Long/Short Alpha Fund stated the following regarding Bloom Energy Corporation (NYSE:BE) in its Q2 2026 investor letter:
"Turning to short positions, detractors from Fund performance were those stocks that rose in price. One of the largest detractors was Bloom Energy Corporation (NYSE:BE). Bloom Energy sells natural, gas-powered fuel cells that help data centers generate power on-site before the centers can connect to the electrical grid. Bloom's stock price has increased significantly in recent months, and we believe it is representative of some of the AI-related exuberance in the small cap market."
Bloom Energy Corporation (NYSE:BE) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 116 hedge fund portfolios held Bloom Energy Corporation (NYSE:BE) at the end of the second quarter, up from 91 in the previous quarter. While we acknowledge the potential of Bloom Energy Corporation (NYSE:BE) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#fund
In its second-quarter 2026 investor letter, Wasatch Long/Short Alpha Fund highlighted Bloom Energy Corporation (NYSE:BE). Bloom Energy Corporation (NYSE:BE), designs and manufactures solid-oxide fuel cell systems for clean, reliable, on-site power generation. On September 15, 2026, Bloom Energy Corporation closed at $259.35 per share. Over the past month, Bloom Energy Corporation returned 25.51%, and its shares are up 225.53% over the past year. Bloom Energy Corporation has a market capitalization of $76.39 billion, and its stock has traded within a 52-week range of $61.37 to $351.28.
Wasatch Long/Short Alpha Fund stated the following regarding Bloom Energy Corporation (NYSE:BE) in its Q2 2026 investor letter:
"Turning to short positions, detractors from Fund performance were those stocks that rose in price. One of the largest detractors was Bloom Energy Corporation (NYSE:BE). Bloom Energy sells natural, gas-powered fuel cells that help data centers generate power on-site before the centers can connect to the electrical grid. Bloom's stock price has increased significantly in recent months, and we believe it is representative of some of the AI-related exuberance in the small cap market."
Bloom Energy Corporation (NYSE:BE) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 116 hedge fund portfolios held Bloom Energy Corporation (NYSE:BE) at the end of the second quarter, up from 91 in the previous quarter. While we acknowledge the potential of Bloom Energy Corporation (NYSE:BE) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#fund
10 days ago
As markets anxiously await the outcome of the current FOMC meeting, Treasury yields notched new 19-year highs in trading Tuesday. The closely watched 10-year surpassed 5.0% Tuesday morning in a high not seen since July 2007. Even the 30-year Treasury yield rose sharply, hitting 5.4%, its highest since June 2007.
In addition to worries over persistent, rising core inflation (one of the Fed's preferred inflation measurements), skyrocketing oil prices and shortages create further pressure on Treasuries. Currently, the rolling one-month correlation between the 10-year Treasury yield and front-month WTI (West Texas Intermediate) crude sits at 0.96 per BMO Capital Markets ****** ysis.
Bond yields and oil prices have moved in tandem for much of this year as investors position for the longer-term inflationary impact of higher oil prices. And with major oil execs sounding the alarm on global supply cache shortages and strategic reserves depletion that help to temporarily soften spiking oil prices for consumers, these pricing pressures are likely to continue in the near-term. Saudi Arabia announced the closure of its East-West pipeline that bypassed the Strait of Hormuz after it came under attack late last week, and cancelled some shipments to Europe, reported Reuters.
"Normally, the relationship isn't as clean as it is now, but the geopolitical drivers behind the price of oil and global inflation are so prominent that the normally modest correlation has become much tighter," Steve Sosnick, Chief Strategist, Interactive Brokers told CNBC. "As long as oil prices remain firm and continue to drift higher, this will add pressure to interest rates."
As macro uncertainty continues and inflation persists, bonds and oil/energy will be categories to keep a weather eye towards and could see renewed ETF investor attention. Currently, investors are seizing the opportunity in longer-term bonds, with $9.7 billion flowing into the iShares 20+ Year Treasury Bond ETF (TLT) in the last three months though the fund is only up $3.4 billion net YTD according to FactSet data. It will be a category likely to see action in the wake of the FOMC rate decision. As bond yields climb, prices fall as they move inverse to each other, and should yields climb higher, investors may choose to scoop up longer duration bonds at depreciated prices for future gains. However, an exodus is more likely until the path of rate hikes becomes more certain.
#treasury #longer #higher
In addition to worries over persistent, rising core inflation (one of the Fed's preferred inflation measurements), skyrocketing oil prices and shortages create further pressure on Treasuries. Currently, the rolling one-month correlation between the 10-year Treasury yield and front-month WTI (West Texas Intermediate) crude sits at 0.96 per BMO Capital Markets ****** ysis.
Bond yields and oil prices have moved in tandem for much of this year as investors position for the longer-term inflationary impact of higher oil prices. And with major oil execs sounding the alarm on global supply cache shortages and strategic reserves depletion that help to temporarily soften spiking oil prices for consumers, these pricing pressures are likely to continue in the near-term. Saudi Arabia announced the closure of its East-West pipeline that bypassed the Strait of Hormuz after it came under attack late last week, and cancelled some shipments to Europe, reported Reuters.
"Normally, the relationship isn't as clean as it is now, but the geopolitical drivers behind the price of oil and global inflation are so prominent that the normally modest correlation has become much tighter," Steve Sosnick, Chief Strategist, Interactive Brokers told CNBC. "As long as oil prices remain firm and continue to drift higher, this will add pressure to interest rates."
As macro uncertainty continues and inflation persists, bonds and oil/energy will be categories to keep a weather eye towards and could see renewed ETF investor attention. Currently, investors are seizing the opportunity in longer-term bonds, with $9.7 billion flowing into the iShares 20+ Year Treasury Bond ETF (TLT) in the last three months though the fund is only up $3.4 billion net YTD according to FactSet data. It will be a category likely to see action in the wake of the FOMC rate decision. As bond yields climb, prices fall as they move inverse to each other, and should yields climb higher, investors may choose to scoop up longer duration bonds at depreciated prices for future gains. However, an exodus is more likely until the path of rate hikes becomes more certain.
#treasury #longer #higher
10 days ago
During the September 10 episode of Mad Money, a caller inquired about Mad Money host Jim Cramer's confidence that Arista Networks, Inc. (NYSE:ANET) will not go down the same path as Ciena Corporation. He replied:
Okay, so let me just tell you, Arista is up a lot this year. My confidence is with Jayshree Ullall. I think she's amazing and I think it every time the stock has dipped, if you've noticed it. Since her tenure began, you have to buy it, and I'm not backing away from that. I feel the same way I do now, the way I did, oh man, how many years ago when we first met her. She is money, and the company's fantastic.
In its second quarter, the company shattered records by delivering its first-ever $3 billion quarter, reporting $3.036 billion in revenue, a 38% year-over-year and over 12% sequential increase. Management lifted its full-year 2026 revenue guidance to approximately $12.6 billion, representing roughly 40% annual top-line growth. The acceleration is supported by deep integration into cloud architectures, where Arista Networks, Inc. (NYSE:ANET) expects its dedicated AI fabrics revenue to reach at least $3.5 billion in 2026, supported by more than 100 **** ulative Etherlink customers.
Bottom-line performance remains equally strong, with non-GAAP diluted earnings per share reaching $1.02, driven by a 49.9% non-GAAP operating margin and $1.3 billion in non-GAAP quarterly net income. Arista Networks, Inc. (NYSE:ANET) ended the quarter with roughly $13.3 billion in cash and marketable securities, offering substantial liquidity. However, its $9.7 billion of non-cancellable purchase commitments also increase working-capital and inventory risk as the company secures components ahead of expected AI demand.
The company's financial results remain heavily tied to two hyperscale customers. According to its 10-K filings, Microsoft accounted for 26%, and Meta Platforms generated 16% of total revenue in fiscal 2025, bringing combined spending from these two cloud giants to 42%. It leaves Arista Networks, Inc. (NYSE:ANET) vulnerable to sudden capital expenditure adjustments, vendor diversification shifts, or project delays by its core buyers.
#billion #NYSE #year
Okay, so let me just tell you, Arista is up a lot this year. My confidence is with Jayshree Ullall. I think she's amazing and I think it every time the stock has dipped, if you've noticed it. Since her tenure began, you have to buy it, and I'm not backing away from that. I feel the same way I do now, the way I did, oh man, how many years ago when we first met her. She is money, and the company's fantastic.
In its second quarter, the company shattered records by delivering its first-ever $3 billion quarter, reporting $3.036 billion in revenue, a 38% year-over-year and over 12% sequential increase. Management lifted its full-year 2026 revenue guidance to approximately $12.6 billion, representing roughly 40% annual top-line growth. The acceleration is supported by deep integration into cloud architectures, where Arista Networks, Inc. (NYSE:ANET) expects its dedicated AI fabrics revenue to reach at least $3.5 billion in 2026, supported by more than 100 **** ulative Etherlink customers.
Bottom-line performance remains equally strong, with non-GAAP diluted earnings per share reaching $1.02, driven by a 49.9% non-GAAP operating margin and $1.3 billion in non-GAAP quarterly net income. Arista Networks, Inc. (NYSE:ANET) ended the quarter with roughly $13.3 billion in cash and marketable securities, offering substantial liquidity. However, its $9.7 billion of non-cancellable purchase commitments also increase working-capital and inventory risk as the company secures components ahead of expected AI demand.
The company's financial results remain heavily tied to two hyperscale customers. According to its 10-K filings, Microsoft accounted for 26%, and Meta Platforms generated 16% of total revenue in fiscal 2025, bringing combined spending from these two cloud giants to 42%. It leaves Arista Networks, Inc. (NYSE:ANET) vulnerable to sudden capital expenditure adjustments, vendor diversification shifts, or project delays by its core buyers.
#billion #NYSE #year
10 days ago
Corn futures are trading with contracts fractionally to a penny lower at Tuesday's midday. The CmdtyView national average Cash Corn price was up 3 1/4 cents at $4.87.
The weekly Crop Progress report tallied 86% of the US corn crop dented as of September 13, with 42% listed as mature and harvest at 8% complete. Condition ratings were back up 1 percentage point this week at 57% in good to excellent condition, as the Brugler500 index held steady at 347.
Cattle Bulls Are Back in Business as Futures Prices Rise
Coffee Prices Rebound on Technical Short Covering
Coffee Prices Rise on Technical Short Covering
#covering
The weekly Crop Progress report tallied 86% of the US corn crop dented as of September 13, with 42% listed as mature and harvest at 8% complete. Condition ratings were back up 1 percentage point this week at 57% in good to excellent condition, as the Brugler500 index held steady at 347.
Cattle Bulls Are Back in Business as Futures Prices Rise
Coffee Prices Rebound on Technical Short Covering
Coffee Prices Rise on Technical Short Covering
#covering
10 days ago
Choosing between a clean energy innovator and a traditional oil giant reflects a core tension in today's market. Investors must decide if Bloom Energy (NYSE:BE) or Diamondback Energy (NASDAQ:FANG) is the better buy.
Bloom Energy manufactures solid oxide fuel cells that provide reliable onsite power, targeting the surging demand from artificial intelligence infrastructure. Diamondback Energy focuses on extracting oil and gas from the Permian Basin, prioritizing operational efficiency and shareholder returns. While both operate in the energy **** e, their business models, risk profiles, and valuation metrics differ significantly for 2026 investors.
Bloom Energy serves as a prominent player among renewable energy stocks, focusing on solid oxide technology for onsite electricity and hydrogen production. The company targets large-load customers in the data center, semiconductor, and industrial sectors where power reliability is critical. Key partnerships include an agreement with American Electric Power (NASDAQ:AEP) to provide up to one gigawatt of fuel cells and a financing framework worth nearly $5.0 billion with Brookfield (NYSE:BN).
In FY 2025, Bloom Energy reported revenue of approximately $2.0 billion, which represents a growth rate of roughly 37.3% compared to the prior year. Despite this robust top-line performance, the company reported a net loss of nearly $88.4 million for the same period. This loss widened from a net loss of approximately $29.2 million in FY 2024, although the net margin of negative 4.4% in FY 2025 was a significant improvement over the negative 22.7% margin seen in FY 2023.
As of its December 2025 balance sheet, Bloom Energy holds a debt-to-equity ratio of 3.9x. This ratio measures total debt against shareholder equity, indicating the company relies moderately on borrowed funds to fuel its expansion. The current ratio, which measures a company's ability to cover short-term debts with its short-term **** ets, stands at a strong 6.0x. For FY 2025, free cash flow reached close to $57.2 million, which is the cash remaining after paying for operating costs and equipment investments.
#bloom #million
Bloom Energy manufactures solid oxide fuel cells that provide reliable onsite power, targeting the surging demand from artificial intelligence infrastructure. Diamondback Energy focuses on extracting oil and gas from the Permian Basin, prioritizing operational efficiency and shareholder returns. While both operate in the energy **** e, their business models, risk profiles, and valuation metrics differ significantly for 2026 investors.
Bloom Energy serves as a prominent player among renewable energy stocks, focusing on solid oxide technology for onsite electricity and hydrogen production. The company targets large-load customers in the data center, semiconductor, and industrial sectors where power reliability is critical. Key partnerships include an agreement with American Electric Power (NASDAQ:AEP) to provide up to one gigawatt of fuel cells and a financing framework worth nearly $5.0 billion with Brookfield (NYSE:BN).
In FY 2025, Bloom Energy reported revenue of approximately $2.0 billion, which represents a growth rate of roughly 37.3% compared to the prior year. Despite this robust top-line performance, the company reported a net loss of nearly $88.4 million for the same period. This loss widened from a net loss of approximately $29.2 million in FY 2024, although the net margin of negative 4.4% in FY 2025 was a significant improvement over the negative 22.7% margin seen in FY 2023.
As of its December 2025 balance sheet, Bloom Energy holds a debt-to-equity ratio of 3.9x. This ratio measures total debt against shareholder equity, indicating the company relies moderately on borrowed funds to fuel its expansion. The current ratio, which measures a company's ability to cover short-term debts with its short-term **** ets, stands at a strong 6.0x. For FY 2025, free cash flow reached close to $57.2 million, which is the cash remaining after paying for operating costs and equipment investments.
#bloom #million
10 days ago
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#stage #survival
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#stage #survival
10 days ago
Corn prices are back down 2 to 4 ½ cents on Tuesday morning. Futures posted gains of 1 ¼ to 3 ½ cents across the board on Monday. September futures expired up 1 ¾ cents at $5.12. Open interest was up 10,360 contracts on Monday suggesting new buying. There were 43 deliveries against September corn on the last trade day. The CmdtyView national average Cash Corn price was up 3 1/4 cents at $4.87.
The weekly Crop Progress report tallied 86% of the US corn crop dented as of September 13, with 42% listed as mature and harvest at 8% complete. Condition ratings were back up 1 percentage point this week at 57% in good to excellent condition, as the Brugler500 index held steady at 347.
Cattle Bulls Are Back in Business as Futures Prices Rise
Coffee Prices Rebound on Technical Short Covering
Coffee Prices Rise on Technical Short Covering
#prices #back #rise #technical
The weekly Crop Progress report tallied 86% of the US corn crop dented as of September 13, with 42% listed as mature and harvest at 8% complete. Condition ratings were back up 1 percentage point this week at 57% in good to excellent condition, as the Brugler500 index held steady at 347.
Cattle Bulls Are Back in Business as Futures Prices Rise
Coffee Prices Rebound on Technical Short Covering
Coffee Prices Rise on Technical Short Covering
#prices #back #rise #technical
10 days ago
The Republican speaker of the House, Mike Johnson, announced on Wednesday that he would again cancel votes scheduled for Thursday, sending lawmakers home one day early ahead of the midterm election recess.
The latest change to the legislative schedule means House members will avoid voting on Republican Thomas Massie's resolution to impeach the defense secretary, Pete Hegseth, and comes amid a frenzied attempt to propose legislation on artificial intelligence.
It's the latest round of cancellations at the hands of Johnson, who had already cut the pre-election session short by two weeks. Democrats have reacted angrily, encouraging Johnson to keep lawmakers on Capitol Hill before the midterm recess beginning on Friday.
Related: More Republicans are turning on Iran war as midterms come into view
"I think it shows the cowardice of the Republican party. They are canceling votes to do business for the American people because they are afraid that that impeachment resolution of Pete Hegseth would pass on a bipartisan basis," the Democratic representative Pramila Jayapal told MediasTouch.
#votes #election
The latest change to the legislative schedule means House members will avoid voting on Republican Thomas Massie's resolution to impeach the defense secretary, Pete Hegseth, and comes amid a frenzied attempt to propose legislation on artificial intelligence.
It's the latest round of cancellations at the hands of Johnson, who had already cut the pre-election session short by two weeks. Democrats have reacted angrily, encouraging Johnson to keep lawmakers on Capitol Hill before the midterm recess beginning on Friday.
Related: More Republicans are turning on Iran war as midterms come into view
"I think it shows the cowardice of the Republican party. They are canceling votes to do business for the American people because they are afraid that that impeachment resolution of Pete Hegseth would pass on a bipartisan basis," the Democratic representative Pramila Jayapal told MediasTouch.
#votes #election
10 days ago
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
11 days ago
Corn prices are back down 2 to 4 ½ cents on Tuesday morning. Futures posted gains of 1 ¼ to 3 ½ cents across the board on Monday. September futures expired up 1 ¾ cents at $5.12. Open interest was up 10,360 contracts on Monday suggesting new buying. There were 43 deliveries against September corn on the last trade day. The CmdtyView national average Cash Corn price was up 3 1/4 cents at $4.87.
The weekly Crop Progress report tallied 86% of the US corn crop dented as of September 13, with 42% listed as mature and harvest at 8% complete. Condition ratings were back up 1 percentage point this week at 57% in good to excellent condition, as the Brugler500 index held steady at 347.
Cattle Bulls Are Back in Business as Futures Prices Rise
Coffee Prices Rebound on Technical Short Covering
Coffee Prices Rise on Technical Short Covering
#corn #cents #Monday
The weekly Crop Progress report tallied 86% of the US corn crop dented as of September 13, with 42% listed as mature and harvest at 8% complete. Condition ratings were back up 1 percentage point this week at 57% in good to excellent condition, as the Brugler500 index held steady at 347.
Cattle Bulls Are Back in Business as Futures Prices Rise
Coffee Prices Rebound on Technical Short Covering
Coffee Prices Rise on Technical Short Covering
#corn #cents #Monday
11 days ago
Wasatch Global Investors, an ***** et management company, released its "Long/Short Alpha Fund" Q2 2026 investor letter. The letter can be downloaded here. Small- and mid-cap growth stocks posted significant gains in Q2, led primarily by AI-related companies. The Russell 2500 Index rose 20.26%, while the Wasatch Long/Short Alpha Fund—Investor Class increased by 8.29%. However, the fund faced challenges due to the outperformance of lower-quality companies, which negatively impacted its long positions. Despite trailing the benchmark and some losses in short positions, the fund remains confident in its long portfolio's fundamentals, which have not deteriorated. Additionally, reviewing the Fund's top five holdings could help identify its best picks for 2026.
In its second-quarter 2026 investor letter, Wasatch Long/Short Alpha Fund highlighted Bloom Energy Corporation (NYSE:BE). Bloom Energy Corporation (NYSE:BE), designs and manufactures solid-oxide fuel cell systems for clean, reliable, on-site power generation. On September 15, 2026, Bloom Energy Corporation closed at $259.35 per share. Over the past month, Bloom Energy Corporation returned 25.51%, and its shares are up 225.53% over the past year. Bloom Energy Corporation has a market capitalization of $76.39 billion, and its stock has traded within a 52-week range of $61.37 to $351.28.
Wasatch Long/Short Alpha Fund stated the following regarding Bloom Energy Corporation (NYSE:BE) in its Q2 2026 investor letter:
"Turning to short positions, detractors from Fund performance were those stocks that rose in price. One of the largest detractors was Bloom Energy Corporation (NYSE:BE). Bloom Energy sells natural, gas-powered fuel cells that help data centers generate power on-site before the centers can connect to the electrical grid. Bloom's stock price has increased significantly in recent months, and we believe it is representative of some of the AI-related exuberance in the small cap market."
Bloom Energy Corporation (NYSE:BE) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 116 hedge fund portfolios held Bloom Energy Corporation (NYSE:BE) at the end of the second quarter, up from 91 in the previous quarter. While we acknowledge the potential of Bloom Energy Corporation (NYSE:BE) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#wasatch
In its second-quarter 2026 investor letter, Wasatch Long/Short Alpha Fund highlighted Bloom Energy Corporation (NYSE:BE). Bloom Energy Corporation (NYSE:BE), designs and manufactures solid-oxide fuel cell systems for clean, reliable, on-site power generation. On September 15, 2026, Bloom Energy Corporation closed at $259.35 per share. Over the past month, Bloom Energy Corporation returned 25.51%, and its shares are up 225.53% over the past year. Bloom Energy Corporation has a market capitalization of $76.39 billion, and its stock has traded within a 52-week range of $61.37 to $351.28.
Wasatch Long/Short Alpha Fund stated the following regarding Bloom Energy Corporation (NYSE:BE) in its Q2 2026 investor letter:
"Turning to short positions, detractors from Fund performance were those stocks that rose in price. One of the largest detractors was Bloom Energy Corporation (NYSE:BE). Bloom Energy sells natural, gas-powered fuel cells that help data centers generate power on-site before the centers can connect to the electrical grid. Bloom's stock price has increased significantly in recent months, and we believe it is representative of some of the AI-related exuberance in the small cap market."
Bloom Energy Corporation (NYSE:BE) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. According to our database, 116 hedge fund portfolios held Bloom Energy Corporation (NYSE:BE) at the end of the second quarter, up from 91 in the previous quarter. While we acknowledge the potential of Bloom Energy Corporation (NYSE:BE) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
#wasatch
12 days ago
The lightweight showdown between Renato Moicano and Brian Ortega has been scrapped from Saturday's UFC 331 card in Los Angeles.
Ortega suffered an undisclosed injury and as a result, his fight has been cancelled and Moicano is no longer competing on the card. Instead, Moicano now faces riding lightweight contender Tom Nolan in the main event for the upcoming UFC Fight Night card scheduled on Oct. 31 at the Meta APEX in Las Vegas.
UFC officials announced the news on Monday.
With Moicano vs. Ortega no longer happening, UFC 331, the card is down to 12 total fights with the heavyweight matchup between Gable Steveson and Sean Sharaf now opening the main card on Saturday night.
UFC 331 is headlined by a flyweight ******* le fight as Joshua Van puts his belt up for grabs against former champion Alexandre Pantoja.
#ortega #lightweight #renato
Ortega suffered an undisclosed injury and as a result, his fight has been cancelled and Moicano is no longer competing on the card. Instead, Moicano now faces riding lightweight contender Tom Nolan in the main event for the upcoming UFC Fight Night card scheduled on Oct. 31 at the Meta APEX in Las Vegas.
UFC officials announced the news on Monday.
With Moicano vs. Ortega no longer happening, UFC 331, the card is down to 12 total fights with the heavyweight matchup between Gable Steveson and Sean Sharaf now opening the main card on Saturday night.
UFC 331 is headlined by a flyweight ******* le fight as Joshua Van puts his belt up for grabs against former champion Alexandre Pantoja.
#ortega #lightweight #renato
12 days ago
Ben Shelton's run at the 2026 US Open was filled with highlights, including his epic five set win over Carlos Alcaraz in the quarterfinals.
However, in the US Open final against Alexander Zverev, tennis fans are wondering about a decision he made and if it ultimately derailed his chance to win the ******* le.
MORE: Tennis season not over after 2026 US Open, tournaments continue through November
The American won the coin toss. He decided to serve first. In a normal match, this is an excellent decision because Shelton's serve is among the best on the ATP Tour.
September 13, 2026; New York, United States; Ben Shelton of the U.S. serves during his men's singles final match against Germany's Alexander Zverev. Mandatory Credit: Geoff Burke-Imagn Images
#tennis #final #match #carlos
However, in the US Open final against Alexander Zverev, tennis fans are wondering about a decision he made and if it ultimately derailed his chance to win the ******* le.
MORE: Tennis season not over after 2026 US Open, tournaments continue through November
The American won the coin toss. He decided to serve first. In a normal match, this is an excellent decision because Shelton's serve is among the best on the ATP Tour.
September 13, 2026; New York, United States; Ben Shelton of the U.S. serves during his men's singles final match against Germany's Alexander Zverev. Mandatory Credit: Geoff Burke-Imagn Images
#tennis #final #match #carlos
